Setrobuvir  (Synonyms: ANA598)

Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC₅₀s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition^[1][2].

Setrobuvir (ANA598) is a non-nucleoside inhibitor that binds to the palm pocket of the HCV polymerase and has an EC₅₀ against HCV genotype 1b/Con1-containing subgenomic replicons in the nanomolar range. Setrobuvir appears to inhibit both de novoinitiated RNA synthesis and primer extension, and its activity is unchanged by the presence of mutations that modify the activity of thumb-binding non-nucleoside inhibitors^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

560.62

C₂₅H₂₅FN₄O₆S₂

1071517-39-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yi G, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012;56(2):830‐837.  [Content Brief]

  [2]. Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silicoperspective [published online ahead of print, 2020 May 6]. J Biomol Struct Dyn. 2020;1‐9.  [Content Brief]